Other equities analysts have also recently issued research reports about the company. BTIG Research boosted their price target on Axsome Therapeutics to $25.00 and gave the stock a buy rating in a report on Thursday, March 28th. Svb Leerink began coverage on Axsome Therapeutics in a report on Monday, April 8th. They set an outperform rating and a $25.00 price target for the company. Zacks Investment Research raised Axsome Therapeutics from a sell rating to a hold rating in a report on Wednesday, May 8th. SunTrust Banks began coverage on Axsome Therapeutics in a report on Tuesday, May 28th. They set a buy rating for the company. Finally, Leerink Swann began coverage on Axsome Therapeutics in a report on Monday, April 8th. They set an outperform rating and a $25.00 price target for the company. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $30.83.
NASDAQ:AXSM opened at $22.83 on Wednesday. The firm has a market cap of $764.36 million, a PE ratio of -19.85 and a beta of 2.78. The company has a quick ratio of 5.68, a current ratio of 5.68 and a debt-to-equity ratio of 1.08. Axsome Therapeutics has a fifty-two week low of $1.94 and a fifty-two week high of $26.45.
In other news, CFO Nick Pizzie bought 1,920 shares of the stock in a transaction on Tuesday, June 11th. The stock was acquired at an average price of $20.80 per share, with a total value of $39,936.00. Following the acquisition, the chief financial officer now directly owns 1,920 shares in the company, valued at $39,936. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark E. Saad bought 3,500 shares of the stock in a transaction on Thursday, May 23rd. The stock was purchased at an average cost of $22.33 per share, with a total value of $78,155.00. Following the acquisition, the director now owns 7,002 shares in the company, valued at $156,354.66. The disclosure for this purchase can be found here. Insiders have bought a total of 20,570 shares of company stock valued at $347,837 in the last three months. 27.50% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC acquired a new position in Axsome Therapeutics in the 4th quarter worth about $30,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in Axsome Therapeutics by 113.7% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,400 shares of the company’s stock worth $48,000 after purchasing an additional 1,809 shares in the last quarter. Focused Wealth Management Inc acquired a new position in Axsome Therapeutics in the 1st quarter worth about $64,000. Bank of New York Mellon Corp acquired a new position in Axsome Therapeutics in the 4th quarter worth about $98,000. Finally, Weiss Asset Management LP acquired a new position in Axsome Therapeutics in the 1st quarter worth about $171,000. 44.22% of the stock is owned by institutional investors and hedge funds.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Read More: Understanding Analyst Recommendations
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.